Resveratrol inhibition of varicella-zoster virus replication in vitro

Antiviral Research

Volumn 72, Issue 3, 2006, Pages 171-177

  Docherty, John J ^a   Sweet, Thomas J ^a   Bailey, Erin ^a   Faith, Seth A ^a   Booth, Tristan ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Cell infection; Resveratrol; Varicella zoster virus

Indexed keywords

MESSENGER RNA; PROTEIN IE62; RESVERATROL; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REPLICATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HERPESVIRUS 3, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; PLAQUE ASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; STILBENES; TRANS-ACTIVATORS; VIRAL ENVELOPE PROTEINS; VIRUS ATTACHMENT; VIRUS INACTIVATION; VIRUS REPLICATION;

HUMAN HERPESVIRUS 3;

EID: 33750731937     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.07.004     Document Type: Article

References (34)

1. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., and Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004) 2783-2840
2. Arvin A.M. Varicella-zoster virus. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. fourth ed. vol. 2 (2001), Lippincott Williams & Wilkins, Philadelphia, PA 2731-2768
3. Baek S.J., Wilson L.C., and Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-!) by increasing the expression of p53. Carcinogenesis 23 (2002) 425-434
4. Cao Y., Fu Z.D., Wang F., Liu H.Y., and Han R. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J. Asian Nat. Prod. Res. 7 (2005) 205-213
5. Chen G., Shan W., Wu Y., Ren L., Dong J., and Ji Z. Synthesis and anti-inflammatory activity of resveratrol analogs. Chem. Pharm. Bull. (Tokyo) 53 (2005) 1587-1590
6. Cohrs R.J., Barbour M., and Gilden D.H. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J. Virol. 70 (1996) 2789-2796
7. Disney G.H., and Everett R.D. A herpes simplex virus type 1 recombinant with both copies of the Vmw175 coding sequences replaced by the homologous varicella-zoster virus open reading frame. J. Gen. Virol. 71 (1990) 2681-2689
8. Docherty J.J., Fu M.M., Stiffler B.S., Limperos R.J., Pokabla C.M., and DeLucia A.L. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 43 (1999) 145-155
9. Docherty J.J., Smith J.S., Fu M.M., Stoner T., and Booth T. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res. 61 (2004) 19-26
10. Docherty J.J., Fu M.M., Han J.M., Sweet T.J., Faith S.A., and Booth T. Effect of resveratrol on herpes simplex virus vaginal infection in the mouse. Antiviral Res. 67 (2005) 155-162
11. Donnelly L.E., Newton R., Kennedy G.E., Fenwick P.S., Leung R.H., Ito K., Russell R.E., and Barnes P.J. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am. J. Physiol. Lung Cell. Mol. Physiol. 287 (2004) L774-L783
12. Evers D.L., Wang X., Huong S.-M., Huang D.Y., and Huang E.-S. 3,4′,5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signalling. Antiviral Res. 63 (2004) 85-95
13. Fukao H., Ijiri Y., Miura M., Hashimoto M., Yamashita T., Fukunaga C., Oiwa K., Kawai Y., Suwa M., and Yamamoto J. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul. Fibrinolysis 15 (2004) 441-446
14. Gilden D.H., Gesser R., Smith J., Wellish M., Laguardia J.J., Cohrs R.J., and Mahalingam R. Presence of VZV and HSV-1 DNA in human nodose and celiac ganglia. Virus Genes 23 (2001) 145-147
15. Gilman S.C., Docherty J.J., Clarke A., and Rawls W.E. Reaction patterns of herpes simplex virus type 1 and type 2 proteins with sera of patients with uterine cervical carcinoma and matched controls. Cancer Res. 40 (1980) 4640-4647
16. Grose C. Varicella vaccination of children in the United States: assessment after the first decade 1995-2005. J. Clin. Virol. 33 (2005) 89-95
17. Heredia A., Davis C., and Redfield R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J. Acquir. Immune Defic. Syndr. 25 (2000) 246-255
18. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R., Moon R.C., and Pezzuto J.M. Cancer chemopreventative activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
19. Kinchington P.R., Hougland J.K., Arvin A.M., Ruyechan W.T., and Hay J. The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J. Virol. 66 (1992) 359-366
20. Krause P., and Klinman D.M. The nature of herpes zoster: a long-term study and new hypothesis. Proc. R. Soc. Med. 58 (1995) 9-12
21. Livak K., and Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25 (2001) 402-408
22. Marier J.F., Chen K., Prince P., Scott G., Del Castillo J.R., and Vachon P. Production of ex vivo lipopolysaccharide-induced tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 is suppressed by trans-resveratrol in a concentration-dependent manner. Can. J. Vet. Res. 69 (2005) 151-154
23. Moriuchi M., Moriuchi H., Straus S.E., and Cohen J.I. Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA. Virology 200 (1994) 297-300
24. Oxman M., Levin M., Johnson G., Schmader K., Straus S., Gelb L., Arbeit R., Simberkoff M., Gershon A., Davis L., Weinberg A., Boardman K., Williams H., Zhang J., Peduzzi P., Beisel C., Morrison V., Guatelli J., Brooks P., Kauffman C., Pachucki C., Neuzil K., Betts R., Wright P., Griffin M., Brunell P., Soto N., Marques A., Keay S., Goodman R., Cotton D., Gnann Jr. J., Loutit J., Holodniy M., Keitel W., Crawford G., Yeh S., Lobo Z., Toney J., Greenberg R., Keller P., Harbecke R., Hayward A., Irwin M., Kyriakides T., Chan C., Chan I., Wang W., Annunziato P., and Silber J. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352 (2005) 2271-2284
25. Palamara A.T., Nencioni L., Aquilano K., DeChiara G., Hernandez L., Cozzolino F., Ciriolo M.R., and Garaci E. Inhibition of influenza A virus replication by resveratrol. J. Infect. Dis. 191 (2005) 1719-1729
26. Sato B., Ito H., Hinchliffe S., Sommer M.H., Zerboni L., and Arvin A.M. Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J. Virol. 77 (2003) 5607-5620
27. Schmidt N.J., and Lennette E.H. Improved yields of cell-free varicella-zoster virus. Infect. Immun. 14 (1976) 709-715
28. Stankus S.J., Dlugopolski M., and Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am. Fam. Physician 61 (2000) 2437-2447
29. Takada Y., Bhardwaj A., Potdar P., and Aggarwal B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23 (2004) 9247-9258
30. Takahashi M., Okuno Y., Otsuka T., Osame J., and Takamizawa A. Development of a live attenuated varicella vaccine. Biken. J. 18 (1975) 25-33
31. Takeuchi H., Baba M., and Shigeta S. An application of tetrazolium (MTT) colorimetric assay for screening of anti-herpes simplex virus compounds. J. Virol. Methods 33 (1991) 61-71
32. Taylor S.L., Kinchington P.R., Brooks A., and Moffat J.F. Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus. J. Virol. 78 (2004) 2853-2862
33. Tyler J.K., and Everett R.D. The DNA binding domain of the varicella-zoster virus gene 62 protein interacts with multiple sequences which are similar to the binding site of the related protein of herpes simplex virus type 1. Nucleic Acids Res. 21 (1993) 513-522
34. Wang J.P., Kurt-Jones E.A., Shin O.S., Manchak M.D., Levin M.J., and Finberg R.W. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J. Virol. 79 (2005) 12658-12666